---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-012381"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:08:01.375398+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Eton Pharmaceuticals amends credit facility: rate reduced, interest-only extended to Nov 2026

## Summary
- Interest rate reduced to SOFR plus 6.55% (from 6.75%); SOFR floor lowered from 5.0% to 2.75%.
- Interest-only period extended to November 2026; optional principal payment in May 2026 or deferral.
- No fees paid to SWK for amendment; maturity unchanged at December 2027.
- Amendment conditions included consummation of Runway/SWK merger; representations and warranties reaffirmed.

## SEC filing metadata
- accession: 0001437749-26-012381
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926012381/0001437749-26-012381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926012381/eton20260409c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-012381
- JSON: https://secwatch.observer/filing/0001437749-26-012381.json
- Plain text: https://secwatch.observer/filing/0001437749-26-012381.txt

## Source-grounded claims
- claim_id: d4750439186bfd75c90b7aacae4571c865d95adb
  claim: Eton Pharmaceuticals, Inc. amended credit facility with SWK Funding LLC at SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0% maturing December 2027.
  evidence_excerpt: On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000143774926012381/0001437749-26-012381-index.htm
- claim_id: 4b088c2158f502487d169e9744e3688600a0fe2d
  claim: Eton Pharmaceuticals, Inc. amended SWK Credit Agreement with SWK Funding LLC (effective 2026-04-09).
  evidence_excerpt: On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000143774926012381/0001437749-26-012381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.